Healey and co-researchers [139] at Swansea University, Wales Cancer Research Centre, developed new RAGE-targeted ADCs and demonstrated their efficacy against ovarian and prostate cancers, which significantly express RAGE, yet lack efficient targeted drugs to treat. This evidence concerns the gene AGER and Familial prostate cancer.